Decreased Blood-brain Barrier P-glycoprotein Function in the Progression of Parkinson's Disease, PSP and MSA

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2008 Feb 13

PMID 18265929

Citations 100

Authors

A L Bartels

A T M Willemsen

R Kortekaas

B M de Jong

R de Vries

O de Klerk

J C H van Oostrom

A Portman

K L Leenders

Affiliations

Soon will be listed here.

Abstract

Decreased blood-brain barrier (BBB) efflux function of the P-glycoprotein (P-gp) transport system could facilitate the accumulation of toxic compounds in the brain, increasing the risk of neurodegenerative pathology such as Parkinson's disease (PD). This study investigated in vivo BBB P-gp function in patients with parkinsonian neurodegenerative syndromes, using [11C]-verapamil PET in PD, PSP and MSA patients. Regional differences in distribution volume were studied using SPM with higher uptake interpreted as reduced P-gp function. Advanced PD patients and PSP patients had increased [11C]-verapamil uptake in frontal white matter regions compared to controls; while de novo PD patients showed lower uptake in midbrain and frontal regions. PSP and MSA patients had increased uptake in the basal ganglia. Decreased BBB P-gp function seems a late event in neurodegenerative disorders, and could enhance continuous neurodegeneration. Lower [11C]-verapamil uptake in midbrain and frontal regions of de novo PD patients could indicate a regional up-regulation of P-gp function.

Citing Articles

Brainstem and cerebellar radiological findings in progressive supranuclear palsy.

Spiegel C, Marotta C, Bertram K, Vivash L, Harding I Brain Commun. 2025; 7(1):fcaf051.

PMID: 39958262 PMC: 11829206. DOI: 10.1093/braincomms/fcaf051.

Ferric Ammonium Citrate Reduces Claudin-5 Abundance and Function in Primary Mouse Brain Endothelial Cells.

Runwal P, Pyun J, Newman S, Mawal C, Bush A, Koehn L Pharm Res. 2025; 42(2):319-334.

PMID: 39939558 PMC: 11880181. DOI: 10.1007/s11095-025-03826-2.

LRRK2 G2019S Mutated iPSC-Derived Endothelial Cells Exhibit Increased α-Synuclein, Mitochondrial Impairment, and Altered Inflammatory Responses.

Sonninen T, Peltonen S, Niskanen J, Hamalainen R, Koistinaho J, Lehtonen S Int J Mol Sci. 2024; 25(23).

PMID: 39684585 PMC: 11641647. DOI: 10.3390/ijms252312874.

Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy.

Lau K, Kotzur R, Richter F Transl Neurodegener. 2024; 13(1):37.

PMID: 39075566 PMC: 11285262. DOI: 10.1186/s40035-024-00430-z.

Pericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders.

Kim H, Wu K, Tam K, Chan Y, Shum D IBRO Neurosci Rep. 2024; 16:147-154.

PMID: 39007089 PMC: 11240299. DOI: 10.1016/j.ibneur.2023.12.007.

References

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin R . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996; 47(1):1-9. DOI: 10.1212/wnl.47.1.1. View

Hendrikse N, Bart J, De Vries E, Groen H, van der Graaf W, Vaalburg W . P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. J Clin Pharmacol. 2001; 41(S7):48S-54S. View

Davis P, Golbe L, Duvoisin R, Schoenberg B . Risk factors for progressive supranuclear palsy. Neurology. 1988; 38(10):1546-52. DOI: 10.1212/wnl.38.10.1546. View

Gelb D, Oliver E, Gilman S . Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56(1):33-9. DOI: 10.1001/archneur.56.1.33. View

Fernandez C, Buyse M, German-Fattal M, Gimenez F . Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci. 2004; 7(3):359-71. View

Lam F, Liu R, Lu P, Shapiro A, Renoir J, Sharom F . beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem. 2001; 76(4):1121-8. DOI: 10.1046/j.1471-4159.2001.00113.x. View

Del Tredici K, Rub U, de Vos R, Bohl J, Braak H . Where does parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol. 2002; 61(5):413-26. DOI: 10.1093/jnen/61.5.413. View

Bartels A, van Berckel B, Lubberink M, Luurtsema G, Lammertsma A, Leenders K . Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(6):505-8. DOI: 10.1016/j.parkreldis.2007.11.007. View

Bain L, Leblanc G . Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol Appl Pharmacol. 1996; 141(1):288-98. DOI: 10.1006/taap.1996.0286. View

10.

Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C . [Consensus on the diagnosis of multi-system atrophy]. Neurologia. 1999; 14(9):425-8. View

11.

Cordon-Cardo C, OBrien J, CASALS D, Biedler J, Melamed M, Bertino J . Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989; 86(2):695-8. PMC: 286540. DOI: 10.1073/pnas.86.2.695. View

12.

Lee J, Markus H . Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy?. Neurology. 2006; 66(1):6-7. DOI: 10.1212/01.wnl.0000196863.43951.44. View

13.

Rajput A . Environmental toxins accelerate Parkinson's disease onset. Neurology. 2001; 56(1):4-5. DOI: 10.1212/wnl.56.1.4. View

14.

Braak H, Braak E . Pathoanatomy of Parkinson's disease. J Neurol. 2000; 247 Suppl 2:II3-10. DOI: 10.1007/PL00007758. View

15.

Piccini P, Pavese N, Canapicchi R, Paoli C, Del Dotto P, Puglioli M . White matter hyperintensities in Parkinson's disease. Clinical correlations. Arch Neurol. 1995; 52(2):191-4. DOI: 10.1001/archneur.1995.00540260097023. View

16.

Kortekaas R, Leenders K, van Oostrom J, Vaalburg W, Bart J, Willemsen A . Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005; 57(2):176-9. DOI: 10.1002/ana.20369. View

17.

Caparros-Lefebvre D, Lees A . Atypical unclassifiable parkinsonism on Guadeloupe: an environmental toxic hypothesis. Mov Disord. 2005; 20 Suppl 12:S114-8. DOI: 10.1002/mds.20553. View

18.

Wegman T, Maas B, Elsinga P, Vaalburg W . An improved method for the preparation of [11C]verapamil. Appl Radiat Isot. 2002; 57(4):505-7. DOI: 10.1016/s0969-8043(02)00143-4. View

19.

Logan J . Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000; 27(7):661-70. DOI: 10.1016/s0969-8051(00)00137-2. View

20.

Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z . Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics. 2003; 13(5):259-63. DOI: 10.1097/01.fpc.0000054087.48725.d9. View